Tazarotene

Tazarotene is a pro-drug of the more water soluble tazarotenic acid and member of the acetylenic class of retinoids; represented by chemical formula: C21H21NO2S. Its chemical name is Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate. Tazarotene is a a receptor-selective and binds to RAR-beta and RAR-gama and weakly to RAR-alpha.Tazarotenic acid does not interconvert to any other retinoids that could potentially activate other retinoid receptors. In psoriasis, tazarotene normalizes keratinocyte differentiation, reverses keratinocyte hyperproliferation and has anti-inflammatory effects. In acne vulgaris, the abnormal desquamation of the follicular epithelium is normalized.

Brands
TRAZENE TRAZENE AZOTEN
Adult Dose
Neonatal
Paedriatic
Characteristics
belongs to acetylenic class of retinoids. It belongs to Anti Acne pharmacological group.The Molecular Weight of Tazarotene is 351.46. Its pKa is 1.5.
Contraindications
Tazarotene is contraindicated in conditions like Pregnancy,Hypersensitivity to the drug.
Effects
The signs and symptoms that are produced after the acute overdosage of Tazarotene include Hypervitaminosis, Redness.The symptomatic adverse reactions produced by Tazarotene are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Erythema, Irritation, Burning, Skin discoloration, Dry skin, Desquamation, Stinging.
Indications
Tazarotene is primarily indicated in conditions like Acne vulgaris, Psoriasis vulgaris.
Interactions
No data regarding the interactions of Tazarotene was found.
Interfrence
Risks
Drug should not be given to Paediatrics, and Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Store Below 30°C.
Warnings
Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when it is used. The possibility that a woman of childbearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mIU/mL for hCG should be obtained within 2 weeks prior toTazarotene therapy, which should begin during a normal menstrual period. Apply only to the affected areas. For external use only. Avoid contact with eyes, eyelids, and mouth. If contact with eyes occurs, rinse thoroughly with water. The safety of use of Tazarotene over more than 20% of body surface area has not been established in psoriasis or acne. Retinoids should not be used on eczematous skin, as they may cause severe irritation. Avoide sunlight. Use sunscreens (minimum SPF of 15) and protective clothing when using it. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using it. It should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.